- likes
- 329
- comments
- 2
Post
Today we reported our third-quarter 2026 financial results, reflecting the strength of our diversified portfolio, disciplined commercial execution and progress across our innovative medicines pipeline. We delivered total revenues of $3.75 billion, a U.S. GAAP net loss of $325 million and adjusted EBITDA of $1.20 billion. Based on these results and our outlook for the remainder of the year, we're once again raising the midpoint of our full-year financial guidance across all metrics. We also advanced our innovative medicines strategy with the planned acquisition of Pacira BioSciences, which is expected to close by the end of November. Read our press release for more information, including non-GAAP financial measure reconciliations and risks related to forward-looking statements. https://viatr.is/4k0hBrh